Artivion (NYSE:AORT) SVP Marshall Stanton Sells 47,376 Shares

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 47,376 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $45.04, for a total value of $2,133,815.04. Following the sale, the senior vice president owned 44,753 shares in the company, valued at $2,015,675.12. The trade was a 51.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Stock Performance

AORT traded up $0.68 on Monday, hitting $45.81. 349,331 shares of the company’s stock were exchanged, compared to its average volume of 432,679. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.04. The firm has a market cap of $2.17 billion, a PE ratio of -109.07 and a beta of 1.65. The stock has a fifty day moving average of $42.97 and a two-hundred day moving average of $37.04. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company’s revenue for the quarter was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Trading of Artivion

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Artivion by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock valued at $128,250,000 after purchasing an additional 232,424 shares in the last quarter. Wellington Management Group LLP raised its holdings in Artivion by 4.1% in the 1st quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company’s stock worth $42,460,000 after acquiring an additional 67,327 shares during the period. Next Century Growth Investors LLC lifted its position in Artivion by 107.6% during the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock worth $25,140,000 after acquiring an additional 530,122 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Artivion by 22.8% during the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after purchasing an additional 119,634 shares during the last quarter. Finally, Invesco Ltd. boosted its position in shares of Artivion by 40.8% in the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after acquiring an additional 139,370 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. JMP Securities increased their target price on shares of Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, October 8th. Citizens Jmp upped their price target on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Finally, Needham & Company LLC raised their price objective on Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.